Cancer cell spheroids as a model to evaluate chemotherapy protocols

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Drug-resistant cancer cells pose a significant challenge in chemotherapy.
• Evaluating the efficacy of combination chemotherapy requires reliable preclinical models.
• Spheroid cultures offer a three-dimensional in vitro model for cancer research.

Purpose of the Study:

• To assess the utility of spheroid cultures for evaluating drug efficacy in cancer.
• To investigate the toxicity and accumulation of doxorubicin, alone and in combination therapies, within spheroid models.
• To determine the impact of drug sequencing on chemotherapy outcomes in spheroid cultures.

Main Methods:

• Utilized spheroid cultures derived from drug-resistant cancer cells.
• Administered free, micellar, and liposomal doxorubicin, both as single agents and in combination with paclitaxel, cisplatin, dexamethasone, mitoxantrone, sclareol, or methotrexate.
• Quantified doxorubicin accumulation via fluorescence and measured cytotoxicity using lactate dehydrogenase release assays.

Main Results:

• Pretreatment of spheroids with mitoxantrone or paclitaxel significantly enhanced doxorubicin accumulation and toxicity.
• The sequence of drug administration in combination therapy critically influenced toxicity levels, with doxorubicin as the initial agent showing the least toxicity.
• Spheroids demonstrated recognition by a cancer cell-specific antibody, validating their biological relevance.

Conclusions:

• Spheroid cultures serve as a valuable tool for predicting the efficacy of chemotherapy combinations.
• Drug-resistant cancer cell spheroids provide a robust platform for preclinical drug screening and combination therapy optimization.
• Understanding drug sequence-dependency is crucial for maximizing therapeutic benefit and minimizing toxicity in combination chemotherapy regimens.